Results 21 to 30 of about 114,702 (262)
Haematologica, 2017 Recurrent infections are common complications in patients with non-Hodgkin lymphomas, for example, chronic lymphocytic leukemia (CLL). The secondary immune defect as the underlying cause of frequent infections is in part due to hypoimmunoglobulinemia or ...
Nicole Stadler +10 more
doaj +2 more sources
Frontiers in Oncology, 2021 Posttransplant lymphoproliferative disorder (PTLD) is a rare complication after allogeneic hematopoietic stem cell transplantation (allo-HSCT) with poor prognosis.
Ting-Ting Yang +17 more
doaj +1 more source
Comparison of Acalabrutinib, A Selective Bruton Tyrosine Kinase Inhibitor, with Ibrutinib in Chronic Lymphocytic Leukemia Cells. [PDF]
Clin Cancer Res, 2017 Patel V +6 more
europepmc +2 more sources
Mechanisms of Resistance to Noncovalent Bruton’s Tyrosine Kinase Inhibitors [PDF]
New England Journal of Medicine, 2022 Covalent (irreversible) Bruton's tyrosine kinase (BTK) inhibitors have transformed the treatment of multiple B-cell cancers, especially chronic lymphocytic leukemia (CLL). However, resistance can arise through multiple mechanisms, including acquired mutations in BTK at residue C481, the binding site of covalent BTK inhibitors.
Eric Wang +34 more
openaire +3 more sources
Spontaneous Spinal Subdural Hematoma Secondary to Hemophilia A and Zanubrutinib
Journal of Neurological Surgery Reports, 2022 Spontaneous spinal subdural hematomas (SSH) are rare occurrences that can occur most commonly secondary to vascular malformations or coagulopathies. Only a small fraction of spontaneous SSHs are caused by acquired coagulation disorders such as leukemia ...
John Lynes +7 more
doaj +3 more sources
Managing toxicities of Bruton tyrosine kinase inhibitors [PDF]
Hematology, 2020 Abstract Inhibition of Bruton’s tyrosine kinase (BTK) has revolutionized the treatment landscape for patients with chronic lymphocytic leukemia (CLL). By targeting this critical kinase in proximal B-cell receptor signaling, BTK inhibitors (BTKis) impair cell proliferation, migration, and activation of NF-κB.
Andrew, Lipsky, Nicole, Lamanna
openaire +2 more sources
Frontiers in Oncology, 2021 Vitreoretinal lymphoma (VRL) is a rare intraocular malignancy, and standard treatment approaches have not been defined yet. Bruton tyrosine kinase inhibitors are found to be effective in the treatment of primary central nervous system diffuse large B ...
Liang Wang, Wenxue Guan, Xiaoyan Peng
doaj +1 more source
Case Report: Therapeutic Use of Ibrutinib in a Patient With Schnitzler Syndrome
Frontiers in Immunology, 2022 Schnitzler syndrome is a rare adult-onset acquired autoinflammatory disorder typically characterized by chronic urticarial rash and immunoglobulin M (IgM) (rarely IgG) monoclonal gammopathy.
Yuehua Huang +6 more
doaj +1 more source
Bruton tyrosine kinase inhibitors for multiple sclerosis
Nature Reviews Neurology, 2023 Current therapies for multiple sclerosis (MS) reduce both relapses and relapse-associated worsening of disability, which is assumed to be mainly associated with transient infiltration of peripheral immune cells into the central nervous system (CNS). However, approved therapies are less effective at slowing disability accumulation in patients with MS ...
Julia Krämer +3 more
openaire +2 more sources
eJHaem, 2021 Chronic lymphocytic leukaemia (CLL) is the most common leukaemia in adults in the UK. Ibrutinib, an oral Bruton tyrosine kinase inhibitor (BTKi) for CLL approved by the UK's National Institute for Health and Care Excellence in January 2017, represented a
Peter Hillmen +6 more
doaj +1 more source